---
title: Evaluation of Rheumatoid Arthritis Disease Education Literature
nct_id: NCT03336684
overall_status: COMPLETED
phase: NA
sponsor: Universiti Sains Malaysia
study_type: INTERVENTIONAL
primary_condition: Rheumatoid Arthritis
countries: Pakistan
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03336684.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03336684"
ct_last_update_post_date: 2020-03-24
last_seen_at: "2026-05-12T06:41:21.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Evaluation of Rheumatoid Arthritis Disease Education Literature

**Official Title:** Evaluation of Rheumatoid Arthritis Disease Education Literature: The ERADEL Trial

**NCT ID:** [NCT03336684](https://clinicaltrials.gov/study/NCT03336684)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 376
- **Lead Sponsor:** Universiti Sains Malaysia
- **Conditions:** Rheumatoid Arthritis
- **Start Date:** 2017-12-18
- **Completion Date:** 2019-06-30
- **CT.gov Last Update:** 2020-03-24

## Brief Summary

Rheumatoid arthritis is an inflammatory disease that results in joint inflammation, pain and swelling. It may progress to advance stages that render patients unable to carry out their daily activities. It also results in joints deformity and is a leading cause of disability globally.

Patient education plays an important role in the management of disease. Adequate patient knowledge and awareness about disease may help in incorporating the ailment in daily life. The purpose of this study is to evaluate the benefit of a disease education literature in Urdu language and with culturally relevant illustration for rheumatoid arthritis patients.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

1. Out-patients with established diagnosis of rheumatoid arthritis over 3 months.
2. Participants who are willing to participate in the study.

Exclusion Criteria:

1. Patients with no rheumatoid arthritis.
2. Patients currently undergoing surgery or had previous history of surgery.
3. Patients who are not willing to participate.
4. In-patients.
```

## Arms

- **Patient Education Group** (EXPERIMENTAL) — Patients will be provided with disease education literature
- **Normal Group** (NO_INTERVENTION) — Patients will not be provided with disease education literature

## Interventions

- **Patient education** (BEHAVIORAL) — Rheumatoid arthritis patients will be provided with disease education literature

## Primary Outcomes

- **Patient knowledge about rheumatoid arthritis** _(time frame: 3 months)_ — Measurement of patient's knowledge and awareness about rheumatoid arthritis using The 13-item Rheumatoid Arthritis Knowledge Assessment Scale (RAKAS-13) before and after the intervention.

The RAKAS-13 is a psychometric tool consisting of 13 multiple choice questions related to rheumatoid arthritis disease knowledge. All questions have 1 point for "Right" answer and zero (0) points for "Wrong" answer.

The scoring criteria are as follows:

Excellent knowledge More than 75% correct answers = Above 11 points

Adequate knowledge More than 50% or equal to 75% correct answers = 8 - 10 points

Low knowledge More than 30% or equal to 50% correct answers = 5 - 7 points

Poor knowledge Less than 30% correct answers = 4 points or less.

## Secondary Outcomes

- **Patient satisfaction** _(time frame: 3 months)_

## Locations (2)

- Clifton Central Hospital, Karachi, Sindh, Pakistan
- Liaqat National Hospital, Karachi, Sindh, Pakistan

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.clifton central hospital|karachi|sindh|pakistan` — added _(2026-05-12)_
- `locations.liaqat national hospital|karachi|sindh|pakistan` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03336684.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03336684*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*